Home
This site is intended for healthcare professionals
Sign upLog in
MedAll Oncology
MedAll Oncology
Dr.Abhishek Kumar Sharma
Simran Pasha
Pradeep Philip
DR USAMA FAROOQ HANJRA
Chiengkuoy Garrnyeai Ghai
Wara Qazi
Noman Ahmed
Mariam Khaled
Honaida abd alsalam Ahmed
Mariana S. Naeem
Colin Orr
Farah Kanaan
Gannesh Guna Segaran
Mariam Alwadda
Ibrahim khalid Mohamed Ahemd Salim
Mahmoud Elrefaei
Salman Ahmad Ansari
Dr.Abhishek Kumar Sharma
Simran Pasha
Pradeep Philip
DR USAMA FAROOQ HANJRA
Chiengkuoy Garrnyeai Ghai
Wara Qazi
Noman Ahmed
Mariam Khaled
Honaida abd alsalam Ahmed
Mariana S. Naeem
Colin Orr
Farah Kanaan
15 members, 1218 followers
OverviewEvents & videosThreadsResourcesPeopleAbout
Patient Leaflets for Clinical Oncology
1L HER2+ / HR+ MBC: Integration Map
Advanced Prostate Cancer Question Bank
Appraising and Applying Clinical Trial Data in Advanced Prostate Cancer: Key Clinical Summary
Bladder Cancer Advocacy Network (BCAN) - Patient Educational Materials Flyer
Differentiation of emerging endocrine therapies in ER⁺/HER2⁻ mBC based on MoA and clinical role
Emerging Therapies and Multidisciplinary Management in Advanced Prostate Cancer: Key Clinical Summary
HER2+ MBC Updates from San Antonio Breast Cancer Symposium 2025
Key Clinical Summary: BRAF-driven treatment decisions - Biomarker testing in practice
Key Clinical Summary: BRAF-driven treatment decisions - First line personalization and adverse events management
Key Clinical Summary: BRAF-driven treatment decisions - The patient perspective
Key Clinical Summary: Cancer Cachexia Update: Focus on Emerging Therapies
Key Clinical Summary: Cancer Cachexia – The Patient Perspective
Key Clinical Summary: Cancer Cachexia: Early Recognition and Comprehensive Care
Key Clinical Summary: Cancer Cachexia: Multimodal Interventions and Multidisciplinary Management
Key Clinical Summary: Evolution and Rationale for Maintenance De-Escalation in 1L HER2⁺ MBC
Key Clinical Summary: Optimizing Maintenance in HER2+ Metastatic Breast Cancer
Key Clinical Summary: The Role of Endocrine Therapy ± CDK4/6 Inhibitors in HER2+/HR+ MBC 1L Setting
MedAll Education Link
Navigating Treatment Decisions in Metastatic Prostate Cancer: Key Clinical Summary
Optimize post-CDK4/6 sequencing in ER⁺/HER2⁻ mBC based on clinical and molecular resistance patterns
Optimizing Maintenance in HER2+ Metastatic Breast Cancer: A thread
Personalizing Therapy in ER⁺/HER2⁻ Metastatic Breast Cancer via Biomarkers and Evidence-Based Decision-Making
Relapsed/Refractory Multiple Myeloma Question Bank